Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02405117 · ClinicalTrials.gov registry record · NA
A Mobile Behavioral Monitoring Intervention for Bipolar Disorder
A NA study, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT02405117: Completed NA study, sponsored by Northwestern University.
NCT02405117 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02405117, a NA study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will develop and pilot a smartphone intervention, LiveWell, to enhance patient self-management of bipolar disorder and facilitate more efficient, timely care delivery by mental health providers. The intervention uses a mobile application to collect daily self-report and continuous behavioral data and adapts intervention content to create a highly tailored and user-responsive treatment system. Patient data collected by the phone will also be provided to clinicians to allow for better evaluation and targeting of treatment. The goal is to reduce symptoms and prevent relapse in patients with bipolar disorder.
Primary Outcome
Percent time symptomatic will be assessed using ratings that measure the presence and severity of manic and depressive symptoms.
Interventions
- BEHAVIORAL LiveWell System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-01-10 |
| Est. Completion | 2017-04-10 |
| Phase | NA |
What the finished NCT02405117 record still lists
NCT02405117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which LiveWell System is the first listed.
NCT02405117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02405117 about?
NCT02405117 is a clinical study titled "A Mobile Behavioral Monitoring Intervention for Bipolar Disorder". This study will develop and pilot a smartphone intervention, LiveWell, to enhance patient self-management of bipolar disorder and facilitate more efficient, timely care delivery by mental health providers. The intervention uses a mobile application to collect daily self-report and continuous behavio...
What is the current status of trial NCT02405117?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2014-01-10. Estimated completion is 2017-04-10.
What interventions are being tested in trial NCT02405117?
The interventions under investigation include: LiveWell System (BEHAVIORAL).
Who is sponsoring clinical trial NCT02405117?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02405117's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy